HilleVax
HilleVax is a biopharmaceutical company dedicated to developing and commercializing novel vaccines, inspired by legacies of leading vaccine developers to benefit human health globally. The company focuses on advancing a vaccine to protect against norovirus, the most common viral cause of acute gastroenteritis worldwide, aiming to improve global health with a sense of urgency.
Industries
Nr. of Employees
medium (51-250)
HilleVax
321 Harrison Ave 5th Fl. Boston, MA 02118
Products
Clinical-stage norovirus vaccine candidate
A vaccine candidate developed to prevent norovirus infection; advanced through prior development and currently maintained as a clinical-stage asset.
Clinical-stage norovirus vaccine candidate
A vaccine candidate developed to prevent norovirus infection; advanced through prior development and currently maintained as a clinical-stage asset.
Services
End-to-end internal development and external-partnering for vaccine candidates from preclinical stages through clinical development and commercialization.
End-to-end internal development and external-partnering for vaccine candidates from preclinical stages through clinical development and commercialization.
Expertise Areas
- Vaccine development
- Clinical trial management
- Biologics CMC and manufacturing
- Regulatory strategy and global filings
Key Technologies
- Biologics manufacturing
- CMC development
- Process development and MSAT
- Analytical method and assay development
News & Updates
Norovirus is responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis, causes approximately 700 million cases and 200,000 deaths worldwide annually, and has a global economic burden estimated at $60.3 billion annually.
Norovirus is responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis, causes approximately 700 million cases and 200,000 deaths worldwide annually, and has a global economic burden estimated at $60.3 billion annually.